shelf life raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-12. Anything still debated is marked as such rather than presented as settled.
The mechanisms attributed to semax are inferred from animal and cell studies rather than traced to one confirmed target. The most frequently cited pathway involves increased expression of brain-derived neurotrophic factor and nerve growth factor in hippocampal and cortical tissue. Some work points to engagement of melanocortin receptors, particularly MC4, which the parent ACTH fragment can activate. Effects on dopaminergic and serotonergic signalling have also been reported. No single account explains all observed results, and the relative weight of each pathway remains unsettled.
Published studies examine a fairly narrow set of endpoints. Rodent experiments commonly measure maze learning, infarct volume after induced ischemia, and tissue levels of neurotrophic factors. Clinical reports from Russian centres describe attention, memory and recovery scores in patients after stroke or transient ischemic attack. Most of those human studies are small and few have been repeated by independent groups. Outcome measures differ between studies, which limits direct comparison.
Circulation time for the peptide is short because peptidases cleave it readily. The Pro-Gly-Pro tail is thought to slow breakdown compared with the bare ACTH fragment, but the gain appears modest. Absorption after intranasal dosing is limited, and only a fraction of a dose is expected to reach the central nervous system. Laboratory concentrations therefore sit well above levels achieved systemically, a gap that complicates translation from bench findings to clinical claims.
Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.
The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid from research suppliers |
| Solubility | Freely soluble in water | Also dissolves in aqueous buffers; solutions are used fresh |
| Typical storage temperature | -20 °C for lyophilized powder | Short-term transport at 2-8 °C is common |
| Common analytical method | Reverse-phase HPLC | Paired with mass spectrometry for identity confirmation |
| Common synonyms | ACTH(4-10) analogue; MEHFPGP | N-terminal methionine retained in the chain |
Common degradation pathways include oxidation of the methionine side chain, hydrolysis of the peptide backbone, and aggregation under unfavourable pH or concentration. Stability studies typically monitor the main peak by chromatography and report total related substances as a percentage. Because no official monograph exists, acceptance criteria vary between laboratories, and reported purity values are not directly comparable across suppliers. Analysts therefore document the method, column, and detection wavelength alongside each result, and open questions remain about how much biological activity the oxidised forms retain.
Solid semax is typically supplied as a lyophilised powder that is hygroscopic and sensitive to moisture, light, and repeated temperature cycling. Long-term storage of the dry peptide is generally recommended at approximately -20 degrees Celsius, while shorter working periods may use refrigeration at 2 to 8 degrees Celsius. Vials should remain tightly closed and desiccated when brought to room temperature, because condensation can damage the material before it is weighed. Dividing a batch into aliquots is preferable to thawing one container repeatedly.
Clinical reports describe use in ischaemic stroke, transient ischaemic attack, optic nerve conditions, and cognitive complaints, but most of these studies are small and were conducted in a single region. Systematic reviews have generally described the evidence base as limited in size and variable in methodological quality. Randomised controlled data suitable for international regulatory assessment are scarce. As a result, major treatment guidelines outside Russia do not include the peptide, and interest in it remains largely research-driven rather than routine clinical.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
From about 1989 to 2018, Ontario has reported a deficit almost every year; the province's net debt increased to approximately $311.6 billion (by October 2018); and Ontario's net debt‐to‐GDP ratio grew from 13.4% to about 40.5% in 2018–19. According to an April 11, 2018 Royal Bank of Canada (RBC) report, which was based on figures provided by the Ford government, the revised estimate of Ontario's deficit was $11.7 billion in 2018–2019 and it was projected to decrease by $1.4 billion in 2019–2020 mainly because of "the removal of the $1 billion contingency reserve." At that time, it was projected that the deficit would be "completely eliminated in 2023–2024 with a small surplus of $0.3 billion." By October 2019, the Financial Accountability Officer, Weltman, said that the FAO had been in error when they—and the Ford government—had projected a $11.7-billion deficit that was reported in the spring 2019 budget. By June 2018, Ontario had "Canada's second-highest public debt per person and a growing budget deficit", according to The Economist. In October 2018, the Ontario Finance Department reported that Ontario's public debt per person, at $23,014, had surpassed that of Quebec at $21,606 in the fiscal year 2017–2018. Newfoundland and Labrador's public debt per capita, at $27,761, was the highest in Canada. By 2019, the Ontario Chamber of Commerce reported that Ontario's debt was over $348 billion—representing about 41% of provincial GDP of almost $850 billion. Ontario's GDP is much larger than any of the other provinces and is almost half of Canada's GDP.
The 16-bit A register is the primary arithmetic and logic accumulator. The 16-bit B register is used for double-length arithmetic operations. The 16-bit program counter holds the address of the next instruction. A carry flag indicates arithmetic overflow. A 16-bit X index register provides for modification of the address of operands. The instruction set has 72 arithmetic, logic, I/O and flow-control instructions. Input/output instructions use the A register and separate input and output 16-bit buses. A 10-bit I/O control bus, consisting of 6 bits of device address information and 4 bits of function selection, is used. The basic processor has a single interrupt signal line, and an option provided up to 48 interrupts. In addition to a front-panel display of lights and toggle switches, the system supports different types of input/output devices. A Teletype Model 33 ASR teleprinter can be used as a console I/O device and (in the most basic systems) to load and store data to paper tape. Smaller systems typically use a high-speed paper-tape reader and punch for data storage. The Honeywell family of peripherals included card readers and punches, line printers, magnetic tape, and both fixed-head and removable hard disk drives. A rack-mounted configuration weighs around 120 pounds (54 kg) and used 475 watts of power. Honeywell advertised the system as the first minicomputer selling for less than $10,000. The Honeywell 316 has the distinction of being the first computer displayed at a computer show with semiconductor RAM memory.
Unit I – Bonthapally: The primary manufacturing hub situated in Bonthapally village, Medak District, Telangana, with multiple production blocks including kilo labs and quality assurance laboratories. It holds approvals from major regulatory agencies and supports commercial API production. Unit II – Pashamylaram: A large-scale manufacturing facility comprising multiple production blocks, an engineering workshop, and warehouses. Unit III – Gaddapotharam: A multi-product facility designed for advanced intermediates and APIs, with analytical development and pilot plant capabilities. R&D Centre – Bonthapally: Research and development centre with a team of approximately 360 scientists, pilot labs, and analytical capabilities to catalyze process development and technology transfer.
Sources: en.wikipedia.org
Assam Asimov (アサム・アシモフ, Asamu Ashimofu) and Mugi Grafton (ムギ・グラフトン, Mugi Gurafuton): Two of Reidlich's underlings who work undercover in S.P.D.'s Earth unit as Neo Deka Red (ネオデカレッド, Neo Deka Reddo) and Neo Deka Yellow (ネオデカイエロー, Neo Deka Ierō), respectively, and appear exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After. After failing to kidnap Carrie and being defeated by Deka Blue, Green, Yellow, and Pink, Reidlich forcibly converts Asimov and Grafton into energy to power his Neo Hyper Muscle Gear. Assam Asimov and Mugi Grafton are portrayed by Rakuto Tochihara (栩原 楽人, Tochihara Rakuto) and Mizuho Hata (秦 瑞穂, Hata Mizuho), respectively. Clementian Carrie (クレメント星人キャリー, Kuremento Seijin Kyarī): A girl from Planet Clement, whose inhabitants can enter the bodies of others for concealment, who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After. Two years prior, she and her father accidentally stumbled onto Kruger discovering Kight Reidlich's corruption. After Reidlich killed Carrie's father, Kruger told Carrie to find his team. She went into hiding before eventually coming to Earth in the present. Upon finding the Dekarangers, they escort her to Planet Gowashichoru before confronting Reidlich. Carrie is portrayed by Rino Kobayashi (小林 里乃, Kobayashi Rino). Rui Edogawa (江戸川 塁, Edogawa Rui): A rookie S.P.D.
Generative AI systems have been used in mathematics and computer science to generate candidate computer programs, proofs, constructions, or algorithms. In 2023, Google DeepMind introduced FunSearch, a method for creating computer programs that solve mathematical and algorithmic problems. FunSearch was used to discover new mathematical constructions in the cap set problem and the bin packing problem. In 2023, Google DeepMind introduced AlphaDev, which was used to discover small sorting algorithms that outperformed previously known human benchmarks and have been integrated into the LLVM standard C++ sorting library. In 2025, Google DeepMind introduced AlphaEvolve, an AI system for general-purpose algorithm discovery and optimization. AlphaEvolve uses LLMs to propose code changes, automated evaluators to assess each candidate, and an evolutionary process to iteratively improve algorithms. In 2026, in response to the increasing use of generative AI in mathematical discovery, a group of mathematicians issued the Leiden Declaration on Artificial Intelligence and Mathematics, which recommends disclosing the use of AI in research papers, ensuring that AI-assisted papers are peer-reviewed, and providing legal resources and public funding so that academia and for-profit companies can compete on equal terms.
== History == Deslorelin was successfully trialed in the U.S. and was approved for veterinary use under certain circumstances. In Europe, it was approved for use in equine assisted reproduction. Ovuplant was withdrawn from the U.S. market following issues with mares which did not become pregnant failing to return to estrus in a timely manner. Techniques were developed where the implant was removed 48 hours after implantation in the mare, however compounded biorelease Deslorelin products were at the time available as well as more commonly used ovulation promoters such as hCG, which did not produce the same failure effect. Upon "Sucromate Equine" receiving FDA-approval, the compounded products were no longer legally available within the U.S., however they remain available in Australia and New Zealand where an approved version is marketed. It is also being trialed in humans to study its efficacy in treatment of breast cancer in women, and in treating precocious puberty and congenital adrenal hyperplasia in male and female children. As of August 2011 this drug was not approved for general use outside the FDA-licensed functions in the U.S., other than within approved clinical trials. Orphan drug status has been designated in the U.S., though approval had not been issued as of 2011.
A stígma (στίγμα) is a mark on the skin. Reported cases of stigmata take various forms. Many show some or all Five Sacred Wounds that were, according to the Bible, inflicted on Jesus during his crucifixion: wounds in the wrists and feet, from nails; and in the side, from a lance. Some stigmatics display wounds to the forehead similar to those caused by the crown of thorns. Stigmata as crown of thorns appearing in the 20th century, e.g. on Marie Rose Ferron, have been repeatedly photographed. Other reported forms include tears of blood or sweating blood, and wounds to the back as from scourging. Many stigmata show recurring bleeding that stops and then starts, at times after receiving Holy Communion; a significant proportion of stigmatics have shown a strong desire to receive Holy Communion frequently. A relatively high percentage of stigmatics also exhibit inedia, claiming to live with minimal (or no) food or water for long periods of time, except for the Holy Eucharist. Some exhibit weight loss, and closer investigation often reveals evidence of fakery. Some stigmatics claim to feel the pain of wounds with no external marks; these are referred to as "invisible stigmata". Some stigmatics' wounds do not appear to clot, and seem to stay fresh and uninfected. The blood from the wounds is said, in some cases, to have a pleasant, perfumed odor, known as the Odour of Sanctity. Individuals who have obtained the stigmata are many times described as ecstatics, overwhelmed with emotions upon receiving the stigmata.
Sources: en.wikipedia.org
It consists mainly of animal experiments and small clinical reports, with much of the clinical material published in Russian-language journals. Large independent trials are scarce. Separating reliable effects from chance findings is consequently difficult.
A fraction of an intranasal dose is thought to reach the central nervous system, and this route is favoured partly for that reason. The proportion is not well characterized. Direct measurement in humans remains difficult with current methods.
Raised BDNF and NGF expression has been reported across several animal studies, which makes the signal fairly consistent. Whether the same change occurs in humans at usable doses is not established. It is best treated as a working hypothesis rather than a confirmed clinical mechanism.
Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.